FDA Panel Considers Easier Access to Peptides Amid Safety Concerns

An advisory panel from the Food and Drug Administration (FDA) has suggested easing restrictions on several peptides, despite warnings from government scientists about inadequate evidence regarding their safety and effectiveness. In recent years, peptides have gained popularity among wellness influencers and celebrities for their alleged antiaging, anti-inflammatory, and longevity-supporting benefits.

Panel Recommendation for Peptides

The panel’s guidance could allow certain pharmacies to produce substances like BPC-157, KPV, and TB-500. These could be provided to patients via prescription. The FDA’s Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding these peptides to the agency’s 503A bulk drug substances list. This vote indicates a nonbinding recommendation. While it does not FDA-approve these peptides as drugs, it could permit state-licensed compounding pharmacies and doctors to produce them under specific conditions. Though the FDA doesn’t have to adhere to the panel’s recommendations, it often does.

Views of Health Secretary and Experts

Health Secretary Robert F. Kennedy Jr. has expressed strong support for peptides, showing intent to change FDA restrictions established under the Biden administration. He also introduced new members to the advisory panel, some of whom reportedly have business interests linked to peptides, according to MedPage Today. Newsweek reached out to the Department of Health and Human Services for comments outside usual working hours.

Some experts strongly oppose the panel’s recommendation. Dr. Pieter Cohen from Harvard University stated to Newsweek that the existing evidence is insufficient to confirm these peptides’ safety for human use. He emphasized the lack of evidence supporting claims of muscle healing, longevity, or antiaging benefits. Concerns remain about their safety in humans, especially if they increase the risk of conditions like cancer or heart disease.

Understanding Peptides

Peptides are short chains of amino acids, much like those forming proteins. Some exist naturally in the body, regulating inflammation, appetite, pigmentation, tissue repair, and hormone signaling. BPC-157, derived from amino acids in human gastric juice, lacks the same structure as known intestinal peptides. A 2025 National Institutes of Health study described it as having antioxidant, anti-inflammatory, and wound-healing properties in animal models, but comprehensive human studies are missing.

KPV, a peptide of three amino acids, comes from an amino acid hormone in the pituitary gland. Research mainly explores its effects on gut, skin, and wound inflammation in models, but these findings aren’t directly applicable to human biology. TB-500 is a synthetic fragment associated with thymosin beta-4, a peptide found in human cells. It’s linked to cardiac repair, stroke recovery, and wound repair in preclinical studies. However, the meaningful human data pertains to full-length thymosin beta-4, not TB-500 as sold in wellness settings, with scant clinical review in humans.

Why Peptides are Popular

Within wellness and biohacking communities, peptides are marketed for muscle recovery, injury healing, antiaging, sleep, energy, and longevity. These claims mostly depend on cell or animal models showing potential in inflammation reduction, oxidative stress relief, wound healing, and tissue regeneration, but human safety and efficacy are unestablished. Market demand is growing. Market Research Future valued the peptides market at $43.12 billion in 2024, projecting growth to $91.79 billion by 2035. The North American market was the largest, though the Asia-Pacific region is growing fastest.

Analysis of U.S. Google searches reveals increased interest in peptides. Peptidesexplorer.com found ‘how to get peptides’ saw a 1,019% surge in search growth from March 2025 to February 2026. ‘Are peptides safe’ had 27,100 searches in February 2026, indicating both rising interest and concerns.

Safety Concerns around Peptides

FDA scientists raise concerns due to limited safety and effectiveness evidence regarding BPC-157, KPV, and TB-500, mentioning that some peptides have uncharacterized chemical identities. They also highlight the immunogenicity risk of injectable formulations, which might trigger immune responses. The panel will vote on three more peptides on Friday: emideltide, semax, and epitalon. Among these, emideltide has extensive research history since 1981, yet, studies remain inconclusive about its benefits. FDA staff noted no identified nonclinical toxicity studies to inform safety for potential clinical emideltide uses.

Drug Review Processes

Cohen criticized the process as a reversal of the usual experimental drug review method—typically involving expert debate over safety and efficacy evidence to assess risk-benefit balance. Experimental drugs without efficacy or safety evidence would generally not reach the panel. When they do, the panel often votes against approval. Cohen argued that these peptide decisions compromise the core FDA principle of approving drugs post-clinical trials, opposing the idea of making peptides available by prescription in this manner.